CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性大细胞淋巴瘤与多发性骨髓瘤中 CAR-T 细胞治疗的失败：紧迫的未满足需求
英文原题：Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need.
查看英文原题
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
自FDA批准以来，嵌合抗原受体（CAR）-T细胞疗法正在改变复发/难治性大细胞淋巴瘤及多发性骨髓瘤的治疗算法格局。虽然最初被誉为游戏规则改变者并受到广泛热烈欢迎，但治疗失败的现实很快成为重大失望。这种情况让患者和临床医生都在思考下一步的治疗选择。侵袭性淋巴瘤或多发性骨髓瘤的CAR-T 细胞疗法失败会导致极差的预后，治疗选择非常有限。然而，新出现的数据显示，使用双特异性抗体和其他策略来挽救受影响患者的方法具有前景。在这篇综述中，我们总结了关于CAR-T 细胞疗法失败后疾病复发或仍难治的患者治疗选择的最新数据，这是一个巨大未满足需求的领域。
展开英文摘要原文
Since its FDA approval, chimeric antigen receptor (CAR)-T cell therapy is changing the landscape of the treatment algorithm for relapsed and refractory large cell lymphoma and multiple myeloma. While initially hailed as a game changer and received widely with great enthusiasm, the reality of treatment failure soon became a major disappointment. This situation left patients and clinicians alike wondering about the next treatment options.
CAR-T cell therapy failure for aggressive lymphoma or multiple myeloma creates a very poor prognosis and the treatment options are very limited. New emerging data, however, show promise for the use of approaches that include bispecific antibodies and other strategies to rescue affected patients. In this review, we summarize the current emerging data on the treatment options for patients whose disease has relapsed or remains refractory after CAR-T cell therapy failure, an area of great unmet need.
论文信息
- 作者
- St Martin Y、Franz JK、Agha ME、Lazarus HM
- 第一作者单位
- Champlain College Saint-Lambert, Montreal, QC, Canada.Canada
- 通讯作者单位
- University of Pittsburgh, Hillman Cancer Center, Pittsburgh, PA, United States of America. Electronic address: aghame@upmc.edu.United States
- 文献类型
- 综述
- 期刊
- Blood reviews2023 Jul
- 原文标识
- PubMed 37173224 · DOI 10.1016/j.blre.2023.101095